Bayer is trading 4.6% up at €49.31 after investors reacted positively to its latest quarterly results, which showed improving operating performance and a more constructive margin outlook.
- The company's latest financial report highlighted a strengthening operational trajectory and a more optimistic outlook for future margins.
- Broader European markets are leaning risk-on following easing geopolitical tensions and supportive macro data, amplifying demand for cyclical healthcare names like Bayer.